Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome:
Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different genetic mutation severity
Longer-term data from both adult patients showed sustained and new improvements across multiple efficacy measures and clinical domains following the completion of steroid taper (patient one: sat unassisted for first time in over a decade, normalized sleep, stabilized seizures; patient two: improved hand stereotypies and breathing, seizure-free for 8.5 months at 25% lower anti-seizure medication)
Initial data from first two pediatric patients showed improvements across multiple efficacy measures and clinical domains, with early evidence of developmental gains (patient one: improved hand function, grasp and gross motor coordination, gained visual reception and receptive language skills; patient two: gained ability to stand up from chair and walk up a stair, increase in seizure-free days)
IDMC approved Company’s request for early advancement to cohort two (high dose) in the REVEAL pediatric trial; dosing expected in Q3 2024 following IDMC review of initial safety data from the first high dose patient in the adolescent and adult trial
Company will host webcast today at 8:00 AM Eastern Time
https://ir.tayshagtx.com/news-relea...apies-announces-positive-clinical-data-across
- Forums
- ASX - By Stock
- NEU
- Competitors to Daybue
Competitors to Daybue, page-9
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$19.91 |
Change
-0.030(0.15%) |
Mkt cap ! $2.544B |
Open | High | Low | Value | Volume |
$19.95 | $20.00 | $19.50 | $8.294M | 417.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 443 | $19.87 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$19.91 | 917 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 3395 | 19.750 |
3 | 6690 | 19.720 |
1 | 1119 | 19.710 |
1 | 1192 | 19.700 |
1 | 1119 | 19.670 |
Price($) | Vol. | No. |
---|---|---|
19.940 | 1119 | 1 |
19.960 | 528 | 1 |
19.980 | 1119 | 1 |
20.000 | 52 | 1 |
20.030 | 1119 | 1 |
Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online